IP Library Granted Patent US 10,844,040
Granted Patent B2
US 10,844,040 · App. 16/723,881 · Granted Nov 24, 2020

Nrf2 activating compounds and uses thereof

Inventors: Matthew Duncton (San Bruno, CA); Rajinder Singh (Belmont, CA)
Assignee: Rigel Pharmaceuticals, Inc.
C07D401/04C07D249/12C07D255/02C07D257/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,844,040
App. No.
16/723,881
Granted
Nov 24, 2020
Kind
B2
Abstract

Aspects of the present disclosure include compounds that activate Nrf2. Such compounds find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Claims (39)

1. A method of treating an autoimmune disease in a subject having said autoimmune disease, the method comprising administering to the subject a pharmaceutically effective amount of a compound of formula (I):

wherein:

X 1 and X 2 are each independently selected from N and CH, wherein at least one of X 1 and X 2 is N;

either Y 1 is sulfonyl and Y 2 is hydrogen, or Y 2 is sulfonyl and Y 1 is hydrogen; and

each R 1 is independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl and R 15 , wherein R 15 comprises a linking group and a compound of formula (I);

or a salt or stereoisomer thereof.

2. The method of claim 1 , wherein said autoimmune disease is multiple sclerosis.

3. The method of claim 1 , wherein said autoimmune disease is psoriasis.

4. The method of claim 3 , wherein said psoriasis is plaque psoriasis.

5. The method of claim 1 , wherein the compound is a compound of formula (II):

or

wherein the compound is a compound of formula (III):

or

wherein the compound is a compound of formula (IV):

6. The method of claim 1 , wherein the sulfonyl is selected from alkyl-SO 2 —, substituted alkyl-SO 2 —, alkenyl-SO 2 —, substituted alkenyl-SO 2 —, cycloalkyl-SO 2 —, substituted cycloalkyl-SO 2 —, heterocycloalkyl-SO 2 —, substituted heterocycloalkyl-SO 2 —, aryl-SO 2 —, substituted aryl-SO 2 —, heteroaryl-SO 2 —, and substituted heteroaryl-SO 2 —.

7. The method of claim 1 , wherein R 1 is alkyl, substituted alkyl, heteroaryl, or substituted heteroaryl.

8. The method of claim 1 , wherein the compound is selected from:

9. A method of treating inflammation in a subject having an inflammation associated with a disease or disorder, the method comprising administering to the subject a pharmaceutically effective amount of a compound of formula (I):

wherein:

X 1 and X 2 are each independently selected from N and CH, wherein at least one of X 1 and X 2 is N;

either Y 1 is sulfonyl and Y 2 is hydrogen, or Y 2 is sulfonyl and Y 1 is hydrogen; and

each R 1 is independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl and R 15 , wherein R 15 comprises a linking group and a compound of formula (I);

or a salt or stereoisomer thereof.

10. The method of claim 9 , wherein said disease or disorder is alcoholic steatohepatitis or non-alcoholic steatohepatitis.

11. The method of claim 10 , wherein said disease or disorder is alcoholic steatohepatitis.

12. The method of claim 10 , wherein said disease or disorder is non-alcoholic steatohepatitis.

13. The method of claim 9 , wherein said disease or disorder is pulmonary arterial hypertension.

14. The method of claim 9 , wherein said disease or disorder is traumatic brain injury.

15. The method of claim 9 , wherein said disease or disorder is radiation exposure.

16. The method of claim 9 , wherein said disease or disorder is exposure to one or more toxic chemicals.

17. The method of claim 9 , wherein said toxic chemical is cyanide.

18. The method of claim 9 , wherein the compound is a compound of formula (II):

or

wherein the compound is a compound of formula (III):

or

wherein the compound is a compound of formula (IV):

19. The method of claim 9 , wherein the sulfonyl is selected from alkyl-SO 2 —, substituted alkyl-SO 2 —, alkenyl-SO 2 —, substituted alkenyl-SO 2 —, cycloalkyl-SO 2 —, substituted cycloalkyl-SO 2 —, heterocycloalkyl-SO 2 —, substituted heterocycloalkyl-SO 2 —, aryl-SO 2 —, substituted aryl-SO 2 —, heteroaryl-SO 2 —, and substituted heteroaryl-SO 2 —.

20. The method of claim 9 , wherein R 1 is alkyl, substituted alkyl, heteroaryl, or substituted heteroaryl.

21. The method of claim 9 , wherein the compound is selected from:

Assignments (2)
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2020
From: DUNCTON, MATTHEW; SINGH, RAJINDER
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 052168/0138 →
Continuity (4)
Continuation 15811088 · Nov 13, 2017
Continuation 15423436 · Feb 2, 2017
Provisional Application 62290748 · Feb 3, 2016
Related Publication 20200216412A1 · Jul 9, 2020